Does tesamorelin build muscle? What the trials show

The short answer: no trial has tested whether tesamorelin builds muscle. The FDA approved trials were designed to shrink visceral fat in adults with HIV, and as a side finding they recorded a gain of about 1.2 to 1.3 kilograms of lean body mass over 26 weeks, compared with a slight loss on placebo. [1] Lean mass is not the same as muscle, no tesamorelin study measured strength, and muscle growth is not an approved use.

This post walks through the body composition findings behind "tesamorelin for muscle growth" searches, what they can and cannot support, and where tesamorelin sits next to other growth hormone axis peptides. It does not give dosing advice; the FDA label dose for the approved use is on the tesamorelin page.

Does tesamorelin help build muscle?

Tesamorelin is a stabilized copy of growth hormone releasing hormone. It signals the pituitary to release more of the body's own growth hormone, which raises IGF-1. [1] Growth hormone and IGF-1 are anabolic signals, which is why tesamorelin gets marketed for muscle.

What the approved trials actually measured:

• Lean body mass at 26 weeks. In the two phase 3 trials, lean body mass rose by 1.3 kilograms and 1.2 kilograms with tesamorelin, compared with changes of minus 0.2 and minus 0.03 kilograms on placebo. [1]
• Trunk fat at 26 weeks. Trunk fat fell by 1.0 and 0.8 kilograms with tesamorelin, compared with small gains on placebo. [1]
• Body weight. Essentially unchanged. The label describes the drug as weight neutral. [1]

So the net pattern was a modest shift in body composition: a little less trunk fat, a little more lean mass, the same weight. The pooled analysis of 806 patients confirms the visceral fat result that the trials were built around, a treatment effect of minus 15.4% at 26 weeks. [2]

Is lean body mass the same as muscle?

No, and this is the key point for anyone searching "tesamorelin muscle growth." Lean body mass on a body composition scan counts everything that is not fat or bone. That includes muscle, organs, and body water.

Growth hormone axis drugs are known to cause fluid retention. The Egrifta WR label lists fluid retention, including edema, joint pain, and carpal tunnel syndrome, as a warning. [1] Some part of a lean mass gain on a growth hormone stimulating drug may therefore be water rather than contractile muscle. The trials did not separate the two.

The broader growth hormone literature shows why this matters. A systematic review of randomized trials in healthy young adults found that growth hormone raised lean body mass by about 2.1 kilograms, yet strength and exercise capacity did not appear to improve, and fluid retention and fatigue were more common. [7] A second systematic review, in healthy older adults, found the same 2.1 kilogram lean mass gain with no change in weight, alongside more swelling, joint pain, carpal tunnel syndrome, and signs of worsening glucose control. [6] The reviewers concluded that growth hormone could not be recommended as an anti-aging therapy. [6]

Tesamorelin raises growth hormone indirectly and more modestly than injected growth hormone, so those results do not transfer one to one. But they show that more lean mass on a scan does not reliably mean more strength.

Did tesamorelin increase muscle size in any study?

One exploratory analysis looked. Researchers re-read CT scans from two earlier randomized HIV trials and measured four trunk muscle groups. Among tesamorelin patients whose visceral fat fell by at least 8%, muscle density rose (meaning less fat marbled inside the muscle) and lean muscle area increased by roughly 0.6 to 1.1 square centimeters per muscle group compared with placebo. [3]

Three limits keep this from being evidence of muscle growth in the everyday sense:

1. It was a secondary, exploratory analysis, not a trial designed to test muscle. [3]
2. It included only tesamorelin responders, which tends to inflate the apparent effect. [3]
3. It measured trunk muscles on a single CT slice, with no strength, function, or performance outcome. The authors called for studies of whether the changes matter in daily life. [3]

For people with muscle loss from illness, the muscle wasting page lists the options with stronger human evidence.

What about people without HIV?

The main non-HIV trial enrolled 60 adults with abdominal obesity and reduced growth hormone secretion. Over 12 months, tesamorelin reduced visceral fat and improved triglycerides and C-reactive protein, with no change in glucose. [4] A substudy of 39 participants found that larger IGF-1 increases were associated with faster phosphocreatine recovery after exercise, a marker of muscle mitochondrial function. [5] That is an association in a small group, not a demonstration of bigger or stronger muscles.

No trial has given tesamorelin to healthy, lean adults who train, which is the group most "tesamorelin for muscle growth" searches come from. Results in that group are extrapolation. Our fat loss and body composition page grades the options by what was actually tested.

Why muscle gain is not an approved use

Egrifta WR is approved for one indication: reducing excess abdominal fat in adults with HIV who have lipodystrophy. The label adds that it is not indicated for weight loss management, and that long-term cardiovascular safety has not been established. [1] Muscle growth, recovery, and athletic performance appear nowhere on the label.

The label also carries warnings that matter more for a healthy person weighing an off-label use. Because tesamorelin raises IGF-1, the label advises monitoring IGF-1 and considering stopping if it stays high, and notes that 47% of patients had IGF-1 above 2 standard deviations after 26 weeks. [1] It can cause glucose intolerance or diabetes, so glucose should be checked before and during treatment, and it must not be used with active cancer. [1]

Any lean mass gained also appears to depend on staying on the drug. Patients switched from tesamorelin to placebo after 26 weeks lost about 1.7 to 1.8 kilograms of lean body mass over the next 26 weeks. [1] Our tesamorelin before and after post covers the full timeline, including fat regain.

Is tesamorelin allowed in sport?

No. Tesamorelin is named on the WADA Prohibited List under section S2 among growth hormone releasing hormone analogues and is prohibited at all times, in and out of competition. [10] The same section covers sermorelin, CJC-1295, and growth hormone secretagogues such as ipamorelin. [10] For recovery questions in tested athletes, the muscle recovery page grades each option by its human evidence.

How tesamorelin compares with other growth hormone peptides for muscle

Every peptide in this family is sold for muscle, and none has a positive muscle trial.

• Sermorelin. In a 16 week trial of 19 adults aged 55 to 71, a sermorelin analog raised growth hormone and IGF-1 and increased lean body mass in men only, with no other body composition change. [8] See sermorelin vs tesamorelin.
• Ipamorelin. Its only randomized human trial tested bowel recovery after surgery and was negative; no human study measured muscle. [9] It was placed on FDA's Category 2 list in 2023 and now has no lawful compounding basis. [11] No trial has tested it combined with tesamorelin; see the tesamorelin and ipamorelin blend page.
• MK-677 and CJC-1295. Compare them directly in tesamorelin vs MK-677 and tesamorelin vs CJC-1295.

Our ranked roundup of peptides for muscle growth puts all of them side by side by human evidence, with WADA status for each.

If you are considering tesamorelin anyway

Tesamorelin is the only peptide in this group with a lawful prescription path today, as Egrifta WR, prescribed for the approved indication or off-label by a licensed clinician. Compounded tesamorelin has no lawful basis, because tesamorelin became a biologic in 2020 and biologics are not eligible for 503A compounding. [12] Our tesamorelin prescription guide explains who qualifies and what a legitimate visit checks, the tesamorelin cost page lists dated prices, and the tesamorelin regulatory tracker logs status changes. For the approved use itself, see HIV lipodystrophy.

For the general picture, what is peptide therapy explains what clinics mean by the term, and how to get peptides prescribed covers the prescription route for every peptide.